Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.
Actively Recruiting
Researchers are conducting a multi-center, prospective, non-interventional study in Germany to collect real-world clinical and patient-reported data from women with primary advanced FIGO stage III or IV or recurrent endometrial cancer receiving first-line treatment. The study evaluates two maintenance therapies following chemotherapy with Carboplatin, Paclitaxel, and Durvalumab CPD, focusing on outcomes in patients with different tumor DNA mismatch repair statuses. The goal is to understand the effectiveness, safety, and patient experiences with these treatments in routine clinical practice. Participants receive first-line CPD chemotherapy. Those with DNA mismatch repair deficient tumors dMMR cohort receive maintenance therapy with durvalumab alone if their disease is controlled after chemotherapy. Participants with DNA mismatch repair proficient tumors pMMR cohort receive maintenance therapy with durvalumab and olaparib under similar conditions. Treatment decisions are based on standard care guidelines and made jointly by patients and their physicians. The study follows patients over time to observe treatment duration and transitions. During the study, participants complete patient-reported outcome questionnaires to assess quality of life and symptom changes after chemotherapy. Clinical data including time to next treatment and progression-free survival are collected up to 46 months. The study also tracks maintenance therapy duration, chemotherapy duration, and timing between chemotherapy and maintenance start. Safety and treatment use are monitored as part of routine care. Overall, the study provides long-term real-world insights into first-line and maintenance therapy for endometrial cancer.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drugs, EXV-802 and EXV-801, for treating agitation in people with Alzheimers Disease dementia. This Phase 23 study uses a double-blind, placebo-controlled design and includes approximately 300 participants diagnosed with Alzheimers-related agitation using standardized criteria and biomarker confirmation. The study is conducted at multiple centers across the US, Canada, and Europe. Participants are randomly assigned to one of three groups receiving EXV-802 capsules, EXV-801 capsules, or placebo capsules, each taken twice daily for six weeks. Screening occurs about four weeks before randomization to ensure eligibility, and the study follows a parallel model comparing these three arms. Treatment adherence and response are carefully monitored during this period. During the study, participants undergo assessments including the Cohen-Mansfield Agitation Inventory CMAI-IPA to measure agitation changes from baseline to week 6, and the Clinical Global Impression of Severity CGI-S scale to evaluate symptom severity. Caregivers must be involved and regularly in contact with participants. Safety and efficacy data are collected throughout, with the study expected to complete by early 2029.